KRAS and lung carcinoma: The pharmacological inhibition of IL-6 in KRAS-mutant lung cancer causes the suppression of tumour progression, STAT3 activation and reduces frequency of tolerogenic macrophages, granulocytic MDSCs and regulatory T cells (Treg)22.